Spruce Biosciences, Inc. (SPRB) has disclosed a new risk, in the Accounting & Financial Operations category.
Spruce Biosciences, Inc. faces significant business risk stemming from the demands of maintaining proper internal controls over financial reporting as mandated by the Sarbanes-Oxley Act. Being a publicly traded entity on Nasdaq subjects them to stringent reporting requirements, which, if not met, could undermine investor confidence and lead to a devaluation of their common stock. The company may incur substantial costs to bolster their accounting functions and management must dedicate considerable effort to comply with Section 404. Any failure to establish and uphold effective internal controls may result in material misstatements in financial reports, potentially triggering regulatory scrutiny and adversely impacting their market standing.
The average SPRB stock price target is $2.33, implying 211.29% upside potential.
To learn more about Spruce Biosciences, Inc.’s risk factors, click here.
